Fortrea Holdings Stock Price, News & Analysis

Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), has announced the appointment of William Sharbaugh to its Board of Directors. Sharbaugh brings over three decades of pharmaceutical industry experience with expertise in finance, operations, manufacturing, and quality.

CEO Anshul Thakral highlighted Sharbaugh's extensive background in CRO and pharmaceutical operations, emphasizing his understanding of stakeholders and global drug development. Sharbaugh expressed his commitment to leveraging his dual experience in CRO and pharmaceutical companies to create value for all stakeholders.

Fortrea (Nasdaq: FTRE), a global contract research organization, has announced the granting of inducement awards to a new employee. The award consists of 75,000 restricted stock units (RSUs) that will vest over three years in equal annual installments, beginning September 12, 2026.

The RSUs are granted under the Company's Amended and Restated 2025 Inducement Award Plan and comply with Nasdaq Listing Rule 5635(c)(4), serving as an employment inducement for the new hire.

Fortrea (Nasdaq: FTRE), a leading contract research organization (CRO), reported its Q2 2025 financial results with revenues of $710.3 million, up from $662.4 million in Q2 2024. The company posted a GAAP net loss of $(374.9) million, largely due to a $309.1 million non-cash goodwill impairment charge.

Key highlights include adjusted EBITDA of $54.9 million and adjusted earnings per share of $0.19. The company reported a book-to-bill ratio of 0.79x for Q2, with a trailing 12-month ratio of 1.10x. Fortrea raised its 2025 revenue guidance to $2,600-$2,700 million while affirming adjusted EBITDA guidance of $170-$200 million.

The company welcomed Anshul Thakral as CEO on August 4, 2025, succeeding Interim CEO Peter M. Neupert, who remains chairman of the Board.

Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), has appointed Tracy Krumme as Senior Vice President of Investor Relations, replacing Hima Inguva. Reporting to CFO Jill McConnell, Krumme will lead the company's global investor relations strategy.

Krumme brings over 30 years of experience in investor relations and capital markets, with significant expertise in the CRO, life sciences, and healthcare sectors. Her previous roles include head of investor relations at PPD (acquired by Thermo Fisher Scientific), Galderma, and Nuance Communications (acquired by Microsoft). She has worked alongside Fortrea's current CEO Anshul Thakral during her tenure at PPD.

Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), has announced employment inducement awards for its new President and CEO, Anshul Thakral, effective August 4, 2025.

The compensation package includes 1,250,000 performance share units (PSUs) that vest after three years subject to performance goals, and 1,250,000 restricted stock units (RSUs) that vest in three equal annual installments. Both awards are contingent on continuous employment or earlier vesting due to change of control and certain termination events.

The grants were approved by independent board members under the Company's 2025 Inducement Award Plan, complying with Nasdaq Listing Rule 5635(c)(4).

Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), has scheduled its second quarter 2025 financial results announcement for Wednesday, August 6, 2025, before market opening. The company will host a conference call at 8:00 am ET the same day.

The earnings call will include a results review and Q&A session. Participants must register through Fortrea's Investor Relations website and are advised to join 10 minutes early. A replay will be available in the events and presentations section after the call.

Fortrea (Nasdaq: FTRE) has announced a strategic collaboration with Emery Pharma to provide rapid lot-by-lot MNP testing of rifampin for drug-drug interaction (DDI) studies. The partnership ensures rifampin impurities remain below FDA's Acceptable Intake Limit.

The collaboration enables sponsors to use rifampin, the preferred agent for DDI studies, by addressing previous concerns about nitrosamine impurity levels. This follows FDA's 2023 guidance updating acceptable MNP limits for rifampin, after their 2021 finding that all tested batches exceeded previous limits.

Through this partnership, Fortrea combines its clinical conduct capabilities with Emery Pharma's GLP and GMP testing expertise to enhance early-phase trial safety and efficiency.

Fortrea (FTRE) has announced the adoption of a limited-duration stockholder rights plan ("poison pill") effective immediately until June 10, 2026. The plan was implemented in response to significant stock price volatility and third-party interest in accumulating shares. Under the plan, stockholders will receive one right per common share as of June 23, 2025. These rights become exercisable if any entity acquires 10% or more of Fortrea's outstanding common stock. When triggered, rights holders can purchase company shares at a 50% discount, excluding the triggering entity. The plan aims to protect stockholder interests, ensure fair treatment in potential takeover situations, and give the Board sufficient time to evaluate any acquisition proposals. Barclays is serving as strategic advisor and Smith Anderson as legal advisor to Fortrea.

Fortrea (FTRE) has appointed Anshul Thakral as its new Chief Executive Officer, effective August 4, 2025. Thakral, who brings over 20 years of life sciences experience, will succeed Interim CEO Peter M. Neupert, who will continue as chairman of the board. The new CEO will focus on executing the company's transformation plan, driving profitable growth, and creating value for customers, employees, and shareholders. Thakral's appointment comes with a board director position, and his extensive background includes roles as an executive, commercial leader, advisor, and entrepreneur in the life sciences sector. The company aims to leverage his expertise in business development and customer engagement to modernize clinical trials and enhance drug development solutions.